Nelida Sjak-Shie

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Hans Mark, Hank H. Yang, Kimberly M. Parker et al. · PubMed · 2003 · 418 citations

Chemotherapeutic Agents, Tumor Biology, Hematological Malignancy +11

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study

Francine M. Foss, Nelida Sjak-Shie, André Goy et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2013 · 73 citations

Identification of polymorphisms of the IκBα gene associated with an increased risk of multiple myeloma

Kimberly M. Parker, Hans Mark, Steven J. Manyak et al. · Cancer Genetics and Cytogenetics · 2002 · 35 citations

Hematological Malignancy, Medicine, Genetics +8

Aprotinin inhibits urokinase but not tissue-type plasminogen activator

Richard Lottenberg, Nelida Sjak-Shie, Asgerally T. Fazleabas et al. · Thrombosis Research · 1988 · 33 citations

Medicine, Mechanism Of Action, Pharmacotherapy +5

LAGλ-1: A clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma

Richard A. Campbell, Steven J. Manyak, Honghao Yang et al. · International Journal of Oncology · 2006 · 30 citations · Full text

Immunology, Immunoediting, Immunotherapy +17